Bet v 1 triggers antiviral-type immune signalling in birch-pollen-allergic individuals.

Autor:	Wisgrill L; Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Fyhrquist N; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.; Human microbiome research program (HUMI), Medicum, University of Helsinki, Helsinki, Finland., Ndika J; Human microbiome research program (HUMI), Medicum, University of Helsinki, Helsinki, Finland., Paalanen L; National Institute for Health and Welfare, Helsinki, Finland.; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland., Berger A; Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria., Laatikainen T; National Institute for Health and Welfare, Helsinki, Finland.; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland., Karisola P; Human microbiome research program (HUMI), Medicum, University of Helsinki, Helsinki, Finland., Haahtela T; Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland., Alenius H; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.; Human microbiome research program (HUMI), Medicum, University of Helsinki, Helsinki, Finland.
Jazyk:	angličtina
Zdroj:	Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology [Clin Exp Allergy] 2022 Aug; Vol. 52 (8), pp. 929-941. Date of Electronic Publication: 2022 Feb 18.
DOI:	10.1111/cea.14108
Abstrakt:	Background: In allergic patients, clinical symptoms caused by pollen remind of symptoms triggered by viral respiratory infections, which are also the main cause of asthmatic exacerbations. In patients sensitized to birch pollen, Bet v 1 is the major symptom-causing allergen. Immune mechanisms driving Bet v 1-related responses of human blood cells have not been fully characterized. Objective: To characterize the immune response to Bet v 1 in peripheral blood in patients allergic to birch pollen. Methods: The peripheral blood mononuclear cells of birch-allergic (n = 24) and non-allergic (n = 47) adolescents were stimulated ex-vivo followed by transcriptomic profiling. Systems-biology approaches were employed to decipher disease-relevant gene networks and deconvolution of associated cell populations. Results: Solely in birch-allergic patients, co-expression analysis revealed activation of networks of innate immunity and antiviral signalling as the immediate response to Bet v 1 stimulation. Toll-like receptors and signal transducer transcription were the main drivers of gene expression patterns. Macrophages and dendritic cells were the main cell subsets responding to Bet v 1. Conclusions and Clinical Relevance: In birch-pollen-allergic patients, the activated innate immune networks seem to be, in part, the same as those activated during viral infections. This tendency of the immune system to read pollens as viruses may provide new insight to allergy prevention and treatment. (© 2022 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF